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Diabetes is associated with a deficit of circulating
endothelial progenitor cells (EPCs), which has been
attributed to their defective mobilization from the bone
marrow. The basis for this mobilization defect is not
completely understood, and we sought to determine if
hyperglycemic conditions enhanced EPC adhesion. We
found that culturing EPCs in high glucose media in-
creased adhesion to bone marrow stromal cells. This
enhanced adhesion was associated with decreased
expression of protein kinase A regulatory subunit 1b
(PRKAR1b), activation of protein kinase A (PKA), and
phosphorylation of a4-integrin on serine 988. This po-
tentiated adhesion was reversed by treatment with a
PKA inhibitor, overexpression of PRKAR1b, or expres-
sion of a phosphorylation-defective a4-integrin variant
(a4[S988A]). Using a model of type 1 diabetes, we
showed that a4(S988A)-expressing mice have more cir-
culating EPCs than their wild-type counterparts. More-
over, diabetic a4(S988A) mice demonstrate enhanced
revascularization after hind limb ischemia. Thus, we
have identified a novel signaling mechanism activating
PKA in diabetes (downregulation of an inhibitory regula-
tory subunit) that leads to deficits of circulating EPCs
and impaired vascular repair, which could be reversed
by a4-integrin mutation.
Cardiovascular disease (CVD) is the leading cause of death
worldwide (1). A dysfunctional endothelium contributes
to the development of CVD by promoting or exacerbating
atherosclerosis, hypertension, and thrombosis. Damage to
the vasculature is repaired in part by a population of bone
marrow stem cells, the endothelial progenitor cells (EPCs).
Several previous studies reported that levels of circulating
EPCs are directly associated with vascular health (2), and
their abundance and functionality are negatively associ-
ated with advanced age (2), smoking (2,3), and a seden-
tary lifestyle (4). Furthermore, several animal (5–7) and
human (8–10) studies have demonstrated an inverse re-
lationship between circulating EPC number and incidence
of diabetes.
EPCs are mobilized from the bone marrow by cytokines
and growth factors such as stromal cell–derived factor-1
(SDF-1a) (6,11) and vascular endothelial growth factor
(VEGF) (12,13). Signaling pathways downstream of these
agonists disrupt adhesive interactions mediated by C-X-C
chemokine receptor 4 (CXCR4) and c-kit, which are partly
responsible for maintaining EPCs in the bone marrow. In
addition, signals from the sympathetic nervous system
have also been implicated in the mobilization of EPCs
(14) as well as hematopoietic stem cells (HSCs) (14,15).
Diabetes is associated with defective progenitor cell mobi-
lization. Prior reports suggest this may result from deficits
of mobilizing agonists (5,16), altered bone marrow struc-
ture and responsiveness (7,17), or induced neuropathy and
altered expression of intracellular signaling molecules (14).
Stem cell populations are also retained in the bone marrow
through a4b1-integrin vascular cell adhesion molecule-1
(VCAM-1) interactions. Ablation of these interactions or con-
ditional a4-integrin knockdown enhanced circulating levels of
both HSCs (18–20) and EPCs (21). Given this prominent role
of a4b1 in bone marrow retention, we hypothesized that
diabetes might impact the functional properties of this
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integrin to limit EPC mobilization. To test this possibility,
we studied the effects of hyperglycemia on the adhesion of
cultured EPCs. We found that growth in high glucose en-
hanced the adhesion of EPCs to bone marrow stromal cells.
This potentiated adhesion was associated with downregula-
tion of the regulatory subunit 1b of protein kinase A
(PRKAR1b), consequent activation of protein kinase A
(PKA), and phosphorylation of a4-integrin on serine 988.
Enhanced adhesion was blocked by a PKA inhibitor and
PRKAR1b overexpression. EPCs with an alanine substitu-
tion at serine 988 (S988A) in the a4-integrin subunit were
also resistant to high glucose–potentiated adhesion. Fur-
thermore, using a model of type 1 diabetes, we observed
that mice expressing the a4(S988A) variant had increased
levels of circulating EPCs and enhanced revascularization
when compared with their wild-type counterparts. Thus,
hyperglycemia limits EPC mobilization through PRKAR1b
downregulation, activation of PKA, phosphorylation of a4-
integrin, and potentiated adhesion in the bone marrow.
Ablation of this signaling pathway enhanced circulating
EPC levels and vascular repair capacity.
RESEARCH DESIGN AND METHODS
Reagents
Antibodies for a4-integrin immunoprecipitation (PS/2
and HP2/1) and blotting (C-20) were from Millipore,
GeneTex, and Santa Cruz Biotechnology, respectively. The
phospho-a4-integrin antibody was generated as previ-
ously described (22). PKA subunit antibodies were sup-
plied by Becton Dickinson. An anti–VCAM-1 antibody was
from Southern Biotech. H89 was obtained from Millipore,
and 8-bromoadenosine cAMP (8-Br-cAMP) was from Enzo
Life Sciences. The PRKAR1b cDNA was obtained from
GeneCopoeia. Streptozotocin (STZ) and anti-actin and
control antibodies were from Sigma-Aldrich.
Cells and Mice
Endothelial colony-forming cells (ECFCs) were obtained
from the Angiogenesis, Endothelial, and Proangiogenic
Cell Core of the Simon Cancer Center at the Indiana
University School of Medicine (23). They were maintained
in EGM-2 media (Lonza) supplemented with 10% FCS and
used between passages 3 and 10. To study the effects of
high glucose, media was supplemented with 20 mmol/L
D-glucose (Sigma-Aldrich) whereas osmotic control media
contained an additional 20 mmol/L L-glucose (VWR). Ex-
ogenous activators (8-Br-cAMP; 500 mmol/L) or inhibitors
(H89; 10 mmol/L) of PKA were added 1 h prior to cell
lysis or biochemical assay. ECFCs were transfected using
the TransFectin reagent (Bio-Rad), according to the manufac-
turer’s recommendations, and used for experiments 48 h later.
Mice expressing the S988A a4-integrin variant a4(S988A)
were generated as previously described (24). To induce
diabetes, STZ was injected intraperitoneally at a dose
of 65 mg/kg for 6 consecutive days. Blood glucose levels
were analyzed after 7 days, and only mice having
a glucose concentration of .350 mg/dL were used for
subsequent analyses. Control mice received injections of
citrate.
Murine bone marrow cells were isolated by flushing
femurs and tibiae with media. EPCs from these prepara-
tions were cultured on fibronectin-coated plates for 1 week
in the above media. Circulating EPCs were detected in lysed
whole blood by flow cytometry using APC-conjugated anti-
Flk and PE-conjugated anti-Sca antibodies (eBioscience).
Biochemical Assays
Measurements of a4-integrin expression and a4b1-integrin
affinity were accomplished by flow cytometry using a
FITC-conjugated anti-a4 antibody (eBioscience) and a
FITC-conjugated affinity ligand (gift from Dr. Larry Sklar,
University of New Mexico), respectively. To measure ad-
hesion, harvested cells were incubated with 5 mmol/L cal-
cein AM (Life Technologies) for 30 min at 37°C. The cells
were then washed, incubated for an additional 30 min,
and washed again. Then 105 cells were added in triplicate
to confluent S17 bone marrow stromal cells (gift from
Dr. Kenneth Dorschkind, University of California, Los
Angeles) in a 24-well plate. At various time points, the
wells were aspirated and washed and fluorescence was
determined in a plate reader. A percent adhesion was
calculated based upon the initial fluorescence of 105 cell
aliquots. Background fluorescence was determined using
wells coated with BSA. PKA activity in cell homogenates
was determined using the PepTag nonradioactive cAMP-
dependent protein kinase assay (Promega). Migration
toward SDF-1a (100 ng/mL) was determined using mod-
ifications of a previously described assay (25).
Hind Limb Ischemia
Revascularization was determined by laser Doppler per-
fusion imaging (LDPI) in mice subjected to hind limb
ischemia (HLI). For HLI, male mice were anesthetized by
isoflurane inhalation (3% isoflurane mixed with 100%
O2), an incision was made through the skin, and the fem-
oral artery and vein were exposed. Sterile 7.0 sutures were
threaded under and around the femoral artery and vein
and knotted to permanently ligate both blood vessels.
Sham HLI surgery was conducted in the same manner,
except that blood vessels were not ligated. Three weeks
after surgery, mice were anesthetized as above and LDPI
(MoorLDI2; Moor Instruments) was recorded for both
ischemic and nonischemic hind limbs. LDPI values scale
linearly with the product of red blood cell velocity and the
number of blood cells within the tissue and are listed in
arbitrary units. Two images were taken for every mouse
and imported into ImageJ, and areas of blue, green, and
red in the region of interest spanning the entire hind
limb were enumerated using the moorFLPI-2 Review
Software. The value for the ischemic limb was then nor-
malized to the nonischemic limb to calculate a percent
recovery of blood perfusion. All procedures were approved
by the University of Louisville Institutional Animal Care
and Use Committee.
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Bone Marrow Transplantation
For bone marrow transplantation, 7-week recipient male
C57BL/6 mice (The Jackson Laboratory) were first condi-
tioned with 950 cGy total body irradiation (g-cell 40;
Nordion, Ontario, Canada). Bone marrow was isolated
from tibias and femurs of donor a4(WT) or a4(S988A)
male mice (12 weeks) by flushing with PBS. The cells were
resuspended in PBS by gentle aspiration through an 18-gauge
needle, filtered through sterile nylon mesh with 100-mM
pores, centrifuged at 1,000 rpm for 10 min at 4°C, and resus-
pended in PBS. Twenty-four hours after irradiation, recipients
were injected with 0.1 mL PBS containing 1 3 107 cells
through the retro-orbital plexus with a 27-gauge needle. Five
weeks after transplant, recipients were characterized for he-
matopoietic recovery by assessing complete blood cell counts
using a HemaVet 950 (Drew Scientific Inc., Oxford, CT).
Immunofluorescence
Skeletal muscle from ischemic limbs was collected, forma-
lin fixed, and paraffin embedded. Sections (5 mm) were
stained with fluorescently conjugated isolectin (Griffonia,
Bandeiraea simplicifolia Lectin I; Vector Laboratories) and
nuclear counterstained with DAPI. Images were acquired
with a fluorescent microscope. Additional sections were
stained with Sirius Red (0.1%; RA Lamb LLC, Apex, NC)
and Fast Green FCF (0.1%; Sigma-Aldrich). Up to three
sections were viewed on an Olympus IOM microscope
and imaged with a SPOT camera using SPOT advanced
image-capture software. Analysis of isolectin staining
and fibrosis was performed using the National Institutes
of Health ImageJ software, version 1.45s. Each digital
photomicrograph (up to three different sections per
slide) was analyzed as previously reported (26). The ex-
tent of fibrosis was measured as the percentage of the
total area assessed (available at https://imagej.nih.gov/ij/
docs/examples/stained-sections/index.html).
Statistical Analysis
Values are expressed as means 6 SE. Statistical signifi-
cance (P, 0.05) was evaluated using an unpaired Student
t test. One-way ANOVA with Bonferroni post hoc test was
used for comparing multiple groups.
Figure 1—Growth in high glucose stimulates ECFC adhesion. A: ECFCs were grown in 25 mmol/L D-glucose or the L-glucose osmotic
control media for 1 week, and a time course of their adhesion to an S17 cell monolayer was determined. n = 4. *P< 0.05. B: Cells grown for
1 week in the indicated media were harvested, and SDF-1a–stimulated migration was analyzed in a transwell assay. C: ECFCs express the
a4-integrin. Solid line, isotype control antibody; dashed line, a4-specific antibody. D: Cells grown for 1 week in the indicated media were
harvested and allowed to adhere for 30 min in the absence or presence of an anti-a4b1 blocking antibody (PS/2) or a nonspecific antibody
(NS). n = 5. *P < 0.05.
diabetes.diabetesjournals.org Abplanalp and Associates 3507
RESULTS
Growth in High Glucose Potentiates EPC Adhesion
Diabetes has been associated with a deficit of circulating
EPCs (5–10). One possible reason for this deficit is enhanced
retention of these cells in the bone marrow, as has been
suggested for HSCs (17). To test this, we first examined
the adhesive properties of cultured EPCs, the ECFCs. To
approximate the serum conditions of diabetes, we grew these
cells in media containing 25 mmol/L D-glucose for 1 week.
These cells demonstrated enhanced adhesion to a monolayer
of S17 bone marrow stromal cells compared with those cells
grown in the osmotic control media (Fig. 1A). Growth in
high glucose media, however, does not induce general cellular
dysfunction. Cells cultured in both types of media displayed
equivalent SDF-1a–mediated migration (Fig. 1B).
a4b1-Integin–mediated adhesion is crucial for main-
taining HSCs (19,27) and EPCs (21) in the bone marrow,
and this integrin is expressed in ECFCs (Fig. 1C). To
determine whether hyperglycemia-stimulated ECFC adhe-
sion is also mediated by a4b1, we performed the adhesion
assay in the presence of a function-blocking antibody (PS/2;
10 mg/mL). Addition of this antibody reduced ECFC adhe-
sion to background levels (Fig. 1D). Inclusion of a nonspecific
antibody had no effect on high glucose–stimulated adhe-
sion. Incubation with either antibody did not affect the
adhesion of the osmotic control cells. Thus, growth in
high glucose stimulates a4b1-dependent adhesion.
Growth in High Glucose Stimulates PKA-Dependent
a4-Integrin Phosphorylation
Enhanced a4b1-mediated adhesion might result from an
increase in a4b1 expression or ligand binding affinity.
However, growth in high glucose media did not appear
to change either of these properties (Fig. 2A and B). Al-
ternatively, a4b1-mediated adhesion can be impacted by
PKA-dependent phosphorylation of the a4-integrin at
serine 988 (22,28). To determine whether growth in
Figure 2—Growth in high glucose simulates PKA activity, a4-integrin phosphorylation, and PKA-dependent adhesion. A: a4 expression. ECFCs
were grown for 1 week in normal media (N), in media containing 25 mmol/L D-glucose (D), or in the osmotic control media (L), and a4-integrin
expression was determined by flow cytometry. n = 4. B: a4b1 affinity. The same cells were used to determine a4b1 affinity by flow cytometry. n = 3.
C: PKA activity. ECFCs were grown in media containing 25 mmol/L D-glucose and the osmotic control media for 1 week, and PKA activity was then
determined. n = 10. *P< 0.05. D: a4 phosphorylation. Cells grown for 1 week in the same media as indicated were treated with DMSO (vehicle) or
the PKA inhibitor H89 and levels of phospho-a4 were determined by Western blotting. Illustrated is a representative blot. E: Illustrated are group
data for high glucose–stimulated a4 phosphorylation. n = 8. *P< 0.05. F: Cell adhesion. Cells grown in D-glucose media were left untreated or were
treated with either H89 or DMSO, and then adhesion to an S17 cell monolayer was determined after 30 min. n = 4. *P < 0.05.
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high glucose increases adhesion through this mechanism,
we first measured PKA activity. Cells grown in 25 mmol/L
D-glucose demonstrated a 1.40 6 0.25–fold increase in
activity compared with cells grown in the osmotic control
media (Fig. 2C). Consistently, we also found an increase in
a4-integrin phosphorylation in the D-glucose–cultured
cells (Fig. 2D and E), which was blocked with the PKA
inhibitor H89 (Fig. 2D and E). To determine whether
there was a causal relationship between PKA activity
and increased adhesion, we treated D-glucose–cultured
cells with H89 prior to their use in the adhesion assay.
We observed that this treatment, but not treatment with
vehicle, reduced adhesion (Fig. 2F). To determine whether
direct PKA activation stimulated a4 phosphorylation and
adhesion, we treated ECFCs with the PKA activator
8-Br-cAMP. Like the high glucose–cultured cells, these
cells demonstrated increased a4 subunit phosphorylation
(Fig. 3A and B) and adhesion (Fig. 3C) compared with
vehicle-treated cells. Moreover, 8-Br-cAMP–stimulated
adhesion was blocked with an a4-integrin function–blocking
antibody and with H89 (Fig. 3C). Finally, S17 cells
express the a4b1 ligand VCAM-1, and an anti–
VCAM-1 blocking antibody also reduced ECFC adhe-
sion to background levels (Fig. 3C). Collectively, these
observations suggest that high glucose stimulates EPC
adhesion by increasing the PKA-mediated phosphory-
lation of the a4-integrin.
PRKAR1b Downregulation Enhances PKA Activity
and Potentiates Adhesion
PKA activation may result from increased levels of its
cellular activator cAMP. However, quantification of cAMP
levels by ELISA indicated no change in the concentration
of this secondary messenger (Fig. 4A). Alternatively, PKA
activity may be influenced by the stoichiometry of its
catalytic and regulatory subunits. To test this possibility,
we first identified which PKA subunits are expressed in
ECFCs. In addition to the catalytic subunit (PKA-C),
ECFCs predominantly express the regulatory subunits
1b (PRKAR1b), 2a (PRKAR2a), and 2b (PRKAR2b)
(Fig. 4B). Next we determined whether the expression
of these subunits was altered by growth in high glucose.
Whereas there were no changes in PKA-C, PRKAR2a, or
PRKAR2b, we did observe a 33 6 12% reduction in
PRKAR1b expression (Fig. 4C and D).
We reasoned that if growth in high glucose down-
regulates PRKAR1b, resulting in PKA activation, a4 phos-
phorylation, and enhanced adhesion, then overexpression
of PRKAR1b should reverse these effects. To test this,
ECFCs cultured in high glucose media were transfected
with PRKAR1b or control vectors. PRKAR1b transfec-
tants demonstrated decreases in PKA activity (Fig. 5A),
a4 phosphorylation (Fig. 5B), and adhesion (Fig. 5C) com-
pared with vector transfectants or untransfected cells.
These observations suggest that attenuated expression
of PRKAR1b in the presence of high glucose enhances
ECFC adhesion.
Ablation of a4-Integrin Phosphorylation Reverses
Hyperglycemia-Induced Adhesion
To directly test the idea that a4-integrin phosphorylation
enhances EPC adhesion in hyperglycemic conditions, we
used cells isolated from mice expressing the a4-integrin
S988A variant. This variant has an alanine rather than
serine at residue 988 and thus cannot be phosphorylated.
Cells from these mice would be predicted to be unre-
sponsive to the effects of hyperglycemia. We tested this
possibility by inducing hyperglycemia in a4(WT) and
a4(S988A) mice using the STZ model of type 1 diabetes
(Fig. 6A). Four weeks after induction of diabetes, bone
Figure 3—Direct PKA stimulation enhances a4 phosphorylation and adhesion. A: PKA-stimulated a4 phosphorylation. Untreated ECFCs or
those treated with 8-Br-cAMP in the presence or absence of H89 were lysed, and levels of phospho-a4 (p-a4) and total a4 determined by
Western blotting. Illustrated are representative blots. B: Illustrated are grouped data of phospho-a4–to–total a4 ratios normalized to
untreated samples. n = 4. *P < 0.05. C: Cell adhesion. Cells variably incubated with 8-Br-cAMP as indicated were allowed to adhere to
an S17 cell monolayer for 30 min. Adhesion was done in the presence of anti-a4 (PS/2), nonspecific (NS), or anti-VCAM antibodies, as
indicated. The PKA dependence of enhanced adhesion was demonstrated by inhibition with H89. n $ 4. *P < 0.05.
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marrow EPCs were isolated, cultured ex vivo, and used for
cellular and biochemical assays. As expected, cells from
both STZ-injected mouse strains demonstrated increased
PKA activity compared with their control, citrate-injected
counterparts (Fig. 6B). However cells isolated from
the diabetic a4(S988A) mice demonstrated a 50 6 5%
reduction in adhesion compared with cells isolated from
the diabetic a4(WT) mice (Fig. 6C). These findings indi-
cate that increased adhesion of EPCs in hyperglycemic
conditions could be attributable to increased a4-integrin
phosphorylation.
S988A Mice Demonstrate Enhanced Revascularization
Potential
The attenuated adhesion of bone marrow EPCs from
diabetic a4(S988A) mice suggests they may be more abun-
dant in circulation. To explore this, we quantified levels of
Flk+/Sca+ cells. Prior to any injection (Fig. 6D), or after
citrate injection (Fig. 6E), there was no significant differ-
ence in the levels of these cells between a4(WT) and
a4(S988A) mice. After induction of diabetes, however (Fig.
6F), we observed that STZ-treated a4(S988A) mice had in-
creased levels of circulating (peripheral blood) Flk+/Sca+ cells
compared with STZ-treated a4(WT) mice. These levels in
the a4(S988A) mice were 3.08-fold greater than levels in
the a4(WT) mice. Reciprocal changes in Flk+/Sca+ cells
were observed in the bone marrow of STZ-treated mice.
These cells were increased in the bone marrow of wild-
type mice compared with circulating levels, but they were
decreased in the bone marrow of S988A animals compared
with circulating levels (Fig. 6F).
Endogenous or exogenous increases in circulating EPCs
promote revascularization (29–32). Thus, increased circu-
lating Flk+/Sca+ cells in diabetic a4(S988A) mice suggests
that these mice might be protected from revascularization
defects. To test this, we subjected diabetic mice of both
strains to HLI and examined the return of vascular perfu-
sion after 3 weeks. We found that blood flow in the ische-
mic limb of a4(S988A) mice had returned to 79.2 6 3.1%
Figure 4—Hyperglycemia and PKA activation. A: cAMP levels. ECFCs grown for 1 week in 25 mmol/L D-glucose (D) or L-glucose (L) as
indicated were analyzed for levels of cAMP by ELISA. n = 3. B: PKA subunits in ECFC. The expression of PKA subunits in ECFC was
determined by Western blotting (top panels). In addition to the catalytic subunit C, these cells predominantly express PRKAR1b, PRKAR2a,
and PRKAR2b (R1b, R2a, and R2b, respectively). Loading control blots (bottom panels) used antibodies for actin (PRKAR1a [R1a], R1b,
R2a, and R2b) or tubulin (PKA-C). C: PKA subunit expression after hyperglycemic growth. ECFCs were cultured for 1 week in 25 mmol/L
D-glucose (D) or L-glucose (L) as indicated, and levels of the indicated PKA subunits (top panels) were determined by Western blotting. D:
Relative expression levels. Illustrated are the relative expression levels of the PKA subunits after hyperglycemic growth. n = 4. *P< 0.05 vs.
L-glucose. C, catalytic subunit C; WB, Western blot.
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of that in the uninjured limb. In contrast, the a4(WT) mice
demonstrated only a 54.86 2.1% recovery (Fig. 7A and B).
Immunohistochemical staining of muscle tissue from
the injured limb also demonstrated an increase in vas-
cular capillaries (isolectin-positive structures) in the
a4(S988A) mice (1.9 6 0.7–fold) compared with the
a4(WT) mice (Fig. 7C and D). In addition, we observed
a greater deposition of collagen fibers in the ischemic
muscle of a4(S988A) mice as compared with the a4(WT)
mice (Fig. 7E and F).
Finally, we assessed whether the enhanced revascular-
ization potential of the a4(S988A) mice was a consequence
of the altered adhesive properties of bone marrow EPCs, or
whether this was an unrelated, inherent property of the
mice themselves. Hence we performed bone marrow trans-
plants with irradiated wild-type recipient mice receiving
Figure 5—Overexpression of PRKAR1b reverses the effect of hyperglycemic culture. ECFCs grown in 25 mmol/L D-glucose for 5 days were
transfected with PRKAR1b (R1b) or control vector (V) and lysed 2 days later. A: PKA activity. The PKA activity of the D-glucose–cultured
transfectants was determined as outlined in RESEARCH DESIGN AND METHODS. n = 4. *P < 0.05. B: a4 Phosphorylation (p-a4). Levels of
phosphorylated a4-integrin in the transfectants were determined by Western blotting. Illustrated is a representative blot. C: Adhesion.
The adhesive properties of the D-glucose–cultured transfectants to an S17 cell monolayer were determined and grouped data illustrated.
n = 6. *P < 0.05.
Figure 6—Characterization of murine EPCs. A: a4(WT) and a4(S988A) mice were injected with citrate or STZ and blood glucose levels
determined after 4 weeks. n $8. *P < 0.05. B: Bone marrow–derived EPCs were then isolated from these mice and cultured, and PKA
activity was quantified. n = 4. *P< 0.05. C: The adhesion of cells from the diabetic mouse strains to an S17 cell monolayer was determined
as above. n = 4. *P < 0.05. D: Levels of Flk+/Sca+ cells were quantified in the peripheral blood of both a4(WT) and a4(S988A) mice prior to
injections. The same cells were then quantified in the peripheral blood (PB) and bone marrow (BM) 4 weeks after injections with citrate (E) or
STZ (F ). n = 8. *P < 0.05.
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either a4(WT) or a4(S988A) bone marrow. After repopu-
lation, the mice were made diabetic by STZ injection and
subjected to HLI, and vascular perfusion was assessed 3 weeks
later. We observed that vascular perfusion in the injured limb
of mice receiving the a4(S988A) bone marrow had returned
to 63.3 6 5.8% of that in the uninjured limb (Fig. 8). In
contrast mice receiving a4(WT) bone marrow demonstrated
only a 48.76 3.1% recovery. These findings suggest that the
expression of a4(S988A) in bone marrow alone is sufficient
for enhancing tissue revascularization in diabetic mice.
DISCUSSION
In this study, we identified a novel mechanism contributing
to a deficit of circulating EPCs in diabetes. Specifically,
growth in high glucose led to the downregulation of
PRKAR1b, with consequent activation of PKA and a4-
integrin phosphorylation. This modification of a4 impacts
a pathway regulating cellular adhesion and migration (28).
On the basis of these observations, we propose that high
levels of phospho-a4, generated under hyperglycemic con-
ditions, promote an overall increase in EPC adhesion,
which presents in vivo as a mobilization defect.
This idea is supported by experiments using ECFCs.
First, when grown in high glucose, these cells demon-
strated enhanced adhesion to bone marrow stromal cells.
Second, this potentiated adhesion was dependent upon
VCAM-1 and a4b1-integrin, consistent with other studies
indicating a major role for this integrin-ligand pair in bone
marrow retention (21,33). Third, ECFCs grown in high
glucose had enhanced PKA activity and PKA-dependent
Figure 7—S988A-expressing mice have potentiated repair capacity. Diabetic a4(WT) or a4(S988A) mice as indicated were subjected to
HLI, and blood perfusion was measured after 3 weeks by LDPI. A: Illustrated are representative scans. NI, nonischemic limb; I, ischemic
limb. B: The perfusion in the ischemic limb was normalized to that of the nonischemic limb and a percentage recovery calculated for each
mouse. Illustrated are the average recoveries. C and D: Isolated muscles from the ischemic limbs were formalin fixed and sections stained
with simplicifolia lectin I (isolectin). Illustrated are representative images (C ) and quantitative data (D). The sections were also stained with
Sirius Red and illustrated are representative images (E) and quantitative data (F ). WT, n = 5; S988A, n = 6. *P < 0.05.
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a4-integrin phosphorylation and adhesion. Finally, the ob-
served increase in PKA activity was associated with the
downregulation of PRKAR1b, and overexpression of this
subunit in high glucose–cultured cells was sufficient to
limit PKA activity and reverse the adhesive phenotype.
These cell culture studies were complemented with
in vivo studies using the STZ model of type 1 diabetes. We
found that EPCs from STZ-treated a4(S988A) mice had
reduced adhesion compared with similar cells from STZ-
treated a4(WT) mice. Consistent with this attenuated
adhesion, diabetic S988A mice demonstrated greater lev-
els of circulating EPCs than their wild-type STZ counter-
parts. This supports the notion that persistent and
systemic vascular injury resulting from hyperglycemia
and signaling molecules thereby released (e.g., VEGF) is
sufficient to mobilize a more loosely adherent bone mar-
row cell population. Finally, consistent with quantitative
increases of circulating EPCs, we observed that a4(S988A)
mice, and mice transplanted with a4(S988A) bone mar-
row, displayed enhanced revascularization after injury.
Several mechanisms may contribute to the defective
mobilization of EPCs in diabetes. First, as identified here,
are increases in progenitor cell adhesiveness. Signaling
pathways engaged upon a4-integrin phosphorylation re-
sult in Rac1 activation, thereby initiating changes in cy-
toskeletal organization, promoting stable adhesion (28).
This signaling mechanism is crucial in migrating cells
where phospho-a4 protein displays a polarized distribu-
tion (22). Although we have not examined the spatial
orientation of phospho-a4 in diabetic EPCs, we propose
that levels are uniformly higher throughout the cell, pro-
moting overall adhesion. It follows then that ablation of
a4 phosphorylation, through S988A expression, would
decrease adhesive strength, consistent with our observa-
tions (Fig. 6C). Further, these loosely adherent cells may
be more responsive to mobilizing cues (VEGF and SDF-
1a), released as a consequence of persistent, diabetes-
induced endothelial damage. Although expression of
a4(S988A) limits bone marrow adhesion and promotes
mobilization, homing and adhesion to the endothelium
may not be impaired. Homing involves primarily b2 fam-
ily integrins (34) and may be independent of a4b1
(21,34). Thus, the increased availability of EPCs in dia-
betic S988A mice (Fig. 6F) and their a4b1-independent
homing to and incorporation at sites of vascular damage
may enable the revascularization we observed in these
animals (Figs. 7 and 8). Alternatively, paracrine factors
released by recruited EPCs may enhance revascularization
potential. Although we did not observe an increase in the
expression of the a4 integrin in hyperglycemic conditions,
another study has reported this (14). The basis for this
discrepancy in a4 expression between studies is not clear.
In addition to a4b1, other adhesion molecules may im-
pact progenitor cell retention in diabetes as well. CD11a,
CD11c, CD49e, CD62L, and ICAM-1 have all been report-
ed to be increased in bone marrow cells of diabetic mice
(14). Interestingly, the same study also reported that
CD62L-deficient mice display increased levels of circulat-
ing CD34+/Flk+ cells. However, a direct role for CD62L in
the bone marrow adhesion of these cells was not demon-
strated and there may be other reasons why the CD62L-
null animals display enhanced CD34+/Flk+ cell levels.
Second, defective EPC mobilization in diabetes may
result from deficits of upstream signaling molecules such
as SDF-1a, VEGF, and nitric oxide (NO) (5,6,16), which
trigger EPC mobilization. Indeed, means to promote NO
production or signaling have been found to enhance mo-
bilization (6,35,36). Among its effects, NO is believed to
activate matrix metalloproteinases (37), which cleave
membrane-bound kit ligand (35,37). Soluble kit ligand
(kitL; stem cell factor) in turn binds its cell surface re-
ceptor, c-kit, enabling cellular release from the bone mar-
row (35,37). In addition, NO has been reported to affect
a4-integrin expression (38) and ligand binding affinity
(39). Although these properties were not affected in our
study, the effects of reduced NO on PKA activity or a4-
integrin phosphorylation are unknown. Moreover, it is
possible that signals downstream of c-kit may impact
Figure 8—Mice transplanted with a4(S988A) bone marrow display greater revascularization. Irradiated, wild-type C57 mice transplanted
with a4(WT) or a4(S988A) bone marrow as indicated were made diabetic and subjected to HLI. Blood perfusion was measured after
3 weeks by LDPI. A: Illustrated are representative scans. NI, nonischemic limb; I, ischemic limb. B: The perfusion in the ischemic limb was
normalized to that of the nonischemic limb and a percentage recovery calculated for each mouse. WT, n = 8; S988A, n = 5. *P < 0.05.
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PKA activity and a4-integrin phosphorylation. Coopera-
tive signaling between growth factor receptors and a4b1 is
not unprecedented. Indeed, it has been demonstrated that
interactions between c-kit and a4b1 signaling pathways
are essential for HSC mobilization (27) and in regulating
neutrophil retention in the bone marrow as well (40).
A final mechanistic basis of diabetes-impaired mobili-
zation may be alterations of bone marrow structure or
responsiveness. Neuropathic outcomes (14) or altered
bone marrow physiology and b-adrenergic signaling (17)
also appear to impede progenitor cell mobilization in di-
abetes. Altered stromal properties in diabetic mice have
been reported in other studies, although a causal relation-
ship to impaired progenitor cell mobilization was not
established (7,41). Thus, diabetes may induce effects on
either the progenitor cells themselves or the bone marrow
to induce selective retention and defective mobilization.
A significant finding in this study is the novel
mechanism upregulating PKA activity in diabetes. Prior
studies using animal models of type 1 diabetes have
demonstrated variable effects on PKA activity. Whereas
some have shown increased activity that is associated
with neuronal dysfunction and abnormal cardiac contrac-
tility (42,43), others have shown decreased activity that
impacts vascular reactivity (44). In addition, a previous
study using bovine aortic endothelial cells demonstrated
that growth in high glucose media led to an increase in
cAMP with presumptive increases in PKA activity, al-
though this was not directly assessed (45). Whereas we
did not observe changes of cAMP in ECFCs, we did ob-
serve changes in PKA subunit expression resulting in mea-
sured increases in enzyme activity. PKA is a tetramer
composed of two catalytic subunits and two inhibitory,
regulatory subunits. Physiological dissociation of the reg-
ulatory subunits, such as that mediated by cAMP, acti-
vates PKA. Alternatively, decreased expression of the
regulatory subunits can alter tetramer stoichiometry,
leading to PKA activation. Such a mechanism seems to
be operative in pituitary adenomas and the Carney com-
plex pathologies, which demonstrate reduced levels of
PRKAR1a (46). Increased PKA signaling in these cases
appears to drive tumorigenesis. Alterations in PKA regu-
latory subunit expression have also been observed in lu-
pus T lymphocytes (47,48) and in Bloom syndrome (49),
although no pathological causality has been demonstrated
in these cases. Finally, a missense mutation in PRKAR1b
has been found to segregate with a familial, late-onset
neurodegenerative disorder (50). Alterations of localized
PKA activity are hypothesized to underlie these neurolog-
ical defects. Thus our work adds to this understanding of
PKA subunit regulation and disease.
Diabetes is a major CVD risk factor and is associated
with impaired wound healing, atherosclerosis, hyperten-
sion, and increased risk of myocardial infarction. At their
core, these outcomes result from a dysfunctional endo-
thelium. Importantly, our studies identify a novel thera-
peutic target to promote endothelial repair and maintain
its health. Therapeutic strategies to restrain PKA activity
and a4-integrin phosphorylation in EPCs would enhance
their mobilization. The increased availability of EPCs
would promote endothelial repair capacity and could ame-
liorate the cardiovascular consequences of diabetes.
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